Federal grants to Novobiotic Pharmaceuticals, LLC
Novobiotic Pharmaceuticals, LLC in Cambridge, Massachusetts received $17.5 million in federal grants from fiscal 2021 to 2025, across 7 awards. Its largest program was Allergy and Infectious Diseases Research, with $13.0 million. In fiscal 2025 it was awarded $1.1 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$17.5 million
- Awards7
- Awarded in FY 2025$1.1 million
- Largest award$6.2 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $3.7 million |
| FY 2022 | 3 | $3.2 million |
| FY 2023 | 4 | $6.9 million |
| FY 2024 | 3 | $2.5 million |
| FY 2025 | 1 | $1.1 million |
Programs that fund Novobiotic Pharmaceuticals, LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 6 | $13.0 million |
| Military Medical Research and Development | 1 | $4.5 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 6 | $13.0 million |
| Department of Defense | 1 | $4.5 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Developing teixobactin for respiratory infections - abstract: the major goal of this proposal is to investigate the potential for teixobactin, our newly discovered antibiotic, to treat respiratory infections. As reported in 2019 by the CDC, pneumonia caused by drug resistant streptococcus pneumoniae | Allergy and Infectious Diseases Research | March 26, 2021 | $6.2 million |
| Late-stage preclinical development of teixobactin to treat drug-resistant infections | Military Medical Research and Development | April 20, 2023 | $4.5 million |
| Teixobactin development for tuberculosis - abstract the goal of this proposal is to investigate the potential for teixobactin (TXB) to treat drug-resistant tuberculosis (TB). Tb is a major global health issue and second largest killer by an infectious agent. Non-compliance by tb patients due to leng | Allergy and Infectious Diseases Research | August 29, 2022 | $3.0 million |
| Teixobactin development for anthrax | Allergy and Infectious Diseases Research | June 22, 2021 | $2.0 million |
| Preclinical development of NOVO29, a new antibiotic | Allergy and Infectious Diseases Research | March 30, 2021 | $977,463 |
| Antifungal discovery from previously uncultivated bacteria - abstract candida auris is a multidrug-resistant yeast that can cause invasive infection and death. It spreads easily between hospitalized patients and nursing home residents. C. Auris is especially hazardous to immunosuppressed patients an | Allergy and Infectious Diseases Research | May 9, 2023 | $595,754 |
| Antibiotic discovery from a new genus of uncultured bacteria. | Allergy and Infectious Diseases Research | March 1, 2021 | $296,521 |
Questions people ask
How much federal grant money does Novobiotic Pharmaceuticals, LLC get?
$17.5 million in 7 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Novobiotic Pharmaceuticals, LLC the most?
The Department of Health and Human Services, with $13.0 million in 6 awards. The Department of Defense follow.
What is Novobiotic Pharmaceuticals, LLC's largest federal grant?
$6.2 million under Allergy and Infectious Diseases Research, with its first action in the period on March 26, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Novobiotic Pharmaceuticals, LLC?
Its largest are Allergy and Infectious Diseases Research and Military Medical Research and Development.
Other grant recipients in Cambridge
- Massachusetts Institute of Technology
- President and Fellows of Harvard College
- The Broad Institute, Inc
- National Bureau of Economic Research Inc
- Smithsonian Institution
- City of Cambridge
- Whitehead Institute for Biomedical Research
- Ada Forsyth Institute, Inc.
Largest federal grant recipients in Massachusetts · Federal grants in Massachusetts